Xilio Therapeutics Inc Spotlight Program Transcript
Good afternoon, and welcome to the Xilio Therapeutics Virtual Program Spotlight. (Operator Instructions) As a reminder, this program is being recorded and a replay will be made available on the Xilio Therapeutics website following the conclusion of today's event.
At this time, I would now like to turn the call over to your host, Stacey Davis, Chief Business Officer at Xilio.
Thank you. Good day, everyone. Welcome to the Xilio Therapeutics Virtual Spotlight event focused on XTX101, a novel Fc-enhanced tumor-activated anti-CTLA-4. Thank you for joining us today. This is Stacey Davis, I'm a Chief Business Officer, and I'll be moderating today's call.
Before we get started, I'd like to remind everyone that the statements we make on this conference call will include forward-looking statements. Actual events or results could differ materially from those expressed or implied by any forward-looking statements as a result of various risks, uncertainties and other factors, including
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |